keyword
https://read.qxmd.com/read/38194487/do-phosphodiesterase-type-5-inhibitors-increase-the-risk-of-biochemical-recurrence-after-radical-prostatectomy
#21
JOURNAL ARTICLE
Jose M Flores, Emily Vertosick, Lawrence C Jenkins, John Cooper, Nicole Benfante, Daniel Sjoberg, Andrew J Vickers, James A Eastham, Vincent P Laudone, Peter T Scardino, Christian J Nelson, John P Mulhall
PURPOSE: There have been conflicting studies on the association between phosphodiesterase type 5 inhibitor (PDE5i) use and biochemical recurrence (BCR) following radical prostatectomy (RP). Our aim was to determine whether PDE5i drug exposure after RP increases the risk of BCR in patients undergoing RP. MATERIALS AND METHODS: An institutional database of prostate cancer patients treated between January 2009 and December 2020 was reviewed. BCR was defined as 2 PSA measurements greater than 0...
January 10, 2024: Journal of Urology
https://read.qxmd.com/read/38167268/pde5-inhibitors-breaking-new-grounds-in-the-treatment-of-covid-19
#22
REVIEW
Ryan Varghese, Gargi Digholkar, Jainam Karsiya, Sahil Salvi, Jeenam Shah, Dileep Kumar, Rohit Sharma
INTRODUCTION: Despite the ever-increasing occurrences of the coronavirus disease (COVID-19) cases around the world, very few medications have been validated in the clinical trials to combat COVID-19. Although several vaccines have been developed in the past quarter, the time elapsed between deployment and administration remains a major impediment. CONTENT: Repurposing of pre-approved drugs, such as phosphodiesterase 5 (PDE5) inhibitors, could be a game-changer while lessening the burden on the current healthcare system...
December 1, 2023: Drug Metabolism and Personalized Therapy
https://read.qxmd.com/read/38148297/princeton-iv-consensus-guidelines-pde5-inhibitors-and-cardiac-health
#23
JOURNAL ARTICLE
Robert A Kloner, Arthur L Burnett, Martin Miner, Michael J Blaha, Peter Ganz, Irwin Goldstein, Noel N Kim, Tobias Kohler, Tom Lue, Kevin T McVary, John P Mulhall, Sharon J Parish, Hossein Sadeghi-Nejad, Richard Sadovsky, Ira D Sharlip, Raymond C Rosen
BACKGROUND: In 1999, 1 year after the approval of the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), the first Princeton Consensus Conference was held to address the clinical management of men with ED who also had cardiovascular disease. These issues were readdressed in the second and third conferences. In the 13 years since the last Princeton Consensus Conference, the experience with PDE5 inhibitors is more robust, and recent new data have emerged regarding not only safety and drug-drug interactions, but also a potential cardioprotective effect of these drugs...
December 26, 2023: Journal of Sexual Medicine
https://read.qxmd.com/read/38146937/efficacy-and-safety-of-pde5-inhibitors-in-middle-aged-and-old-patients-with-and-without-hypogonadism
#24
REVIEW
Chunlin Wang, Hui Zhang, Fu Wang, Jun Guo, Jianlin Yuan, Guangdong Hou, Ming Gao, Zheng Li, Yan Zhang
PURPOSE: Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed. MATERIALS AND METHODS: A thorough examination of existing literature has been conducted on PubMed...
December 2024: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://read.qxmd.com/read/38140135/the-complexity-of-bariatric-patient-s-pharmacotherapy-sildenafil-biopharmaceutics-and-pharmacokinetics-before-vs-after-gastric-sleeve-bypass
#25
JOURNAL ARTICLE
Daniel Porat, Oleg Dukhno, Sandra Cvijić, Arik Dahan
Postbariatric altered gastrointestinal (GI) anatomy/physiology may significantly harm oral drug absorption and overall bioavailability. In this work, sildenafil, the first phosphodiesterase-5 (PDE5) inhibitor, was investigated for impaired postbariatric solubility/dissolution and absorption; this research question is of particular relevance since erectile dysfunction (ED) is associated with higher body mass index (BMI). Sildenafil solubility was determined both in vitro and ex vivo, using pre- vs. postsurgery gastric contents aspirated from patients...
December 18, 2023: Pharmaceutics
https://read.qxmd.com/read/38138293/exploring-the-multifaceted-potential-of-sildenafil-in-medicine
#26
REVIEW
Ciprian Pușcașu, Anca Zanfirescu, Simona Negreș, Oana Cristina Șeremet
Phosphodiesterase type 5 (PDE5) is pivotal in cellular signalling, regulating cyclic guanosine monophosphate (cGMP) levels crucial for smooth muscle relaxation and vasodilation. By targeting cGMP for degradation, PDE5 inhibits sustained vasodilation. PDE5 operates in diverse anatomical regions, with its upregulation linked to various pathologies, including cancer and neurodegenerative diseases. Sildenafil, a selective PDE5 inhibitor, is prescribed for erectile dysfunction and pulmonary arterial hypertension...
December 17, 2023: Medicina
https://read.qxmd.com/read/38086555/a-drug-target-for-erectile-dysfunction-to-help-improve-fertility-sexual-activity-and-wellbeing-mendelian-randomisation-study
#27
JOURNAL ARTICLE
Benjamin Woolf, Skanda Rajasundaram, Héléne T Cronjé, James Yarmolinsky, Stephen Burgess, Dipender Gill
OBJECTIVE: To investigate the association of genetically proxied (using a surrogate biomarker) inhibition of phosphodiesterase 5 (PDE5), an established drug target for erectile dysfunction, with fertility, sexual behaviour, and subjective wellbeing. DESIGN: Two sample cis-mendelian randomisation study. SETTING: Summary data on genetic associations obtained from the International Consortium for Blood Pressure and UK Biobank. PARTICIPANTS: Individuals of European ancestry from the International Consortium for Blood Pressure (n=757 601) for estimating PDE5 inhibition (using the surrogate biomarker of diastolic blood pressure reduction), and UK Biobank (n=211 840) for estimating the fertility, sexual behaviour, and subjective wellbeing outcomes in male participants...
December 12, 2023: BMJ: British Medical Journal
https://read.qxmd.com/read/38060834/identifying-phosphodiesterase-5-inhibitors-with-drug-repurposing-approach-implications-in-vasodysfunctional-disorders
#28
JOURNAL ARTICLE
Mohd Shahnawaz Khan, Hamza Ahmad Mohammad, Moyad Shahwan, Dharmendra Kumar Yadav, Saleha Anwar, Anas Shamsi
Phosphodiesterase type 5 (PDE5) is a multidomain protein that plays a crucial role in regulating cellular cyclic guanosine monophosphate (cGMP), a key signaling molecule involved in various physiological processes. Dysregulation of PDE5 and cGMP signaling is associated with a range of vasodysfunctional disorders, necessitating the development of effective therapeutic interventions. This study adopts comprehensive approach, combining virtual screening and molecular dynamics (MD) simulations, to repurpose FDA-approved drugs as potential PDE5 inhibitors...
December 7, 2023: ChemistryOpen
https://read.qxmd.com/read/38034900/efficacy-of-chinese-herbal-medicine-formula-in-the-treatment-of-mild-to-moderate-erectile-dysfunction-study-protocol-for-a-multi-center-randomized-double-blinded-placebo-controlled-clinical-trial
#29
JOURNAL ARTICLE
Run-Nan Xu, Jian-Xiong Ma, Xin Zhang, Ze-Dong Liao, Yi-Jia Fu, Bo-Dong Lv
INTRODUCTION: Erectile dysfunction (ED) is a prevalent condition in urology, primarily managed with PDE5 inhibitors (PDE5Is). However, approximately 20% of patients do not experience improvement in overall sexual satisfaction (OS) after taking PDE5Is. Among these, traditional Chinese medicine (TCM) has emerged as a complementary approach, with formulas like Hongjing I granules (HJIG) showing promise in preliminary studies. This study aims to rigorously evaluate the effectiveness and safety of HJIG in mild to moderate ED cases, assessing improvement in both sexual function and TCM pattern alignment...
2023: International Journal of General Medicine
https://read.qxmd.com/read/38034088/safety-profile-and-signal-detection-of-phosphodiesterase-type-5-inhibitors-for-erectile-dysfunction-a-food-and-drug-administration-adverse-event-reporting-system-analysis
#30
JOURNAL ARTICLE
Young Eun Shin, Sirikan Rojanasarot, Ana L Hincapie, Jeff Jianfei Guo
BACKGROUND: Phosphodiesterase type 5 inhibitors (PDE5Is) are generally well tolerated but have been associated with uncommon and significant adverse events (AEs). AIM: This study aims to investigate and compare the characteristics of AEs associated with PDE5Is used for erectile dysfunction and identify any safety signals in a postmarketing surveillance database between 2010 and 2021. METHODS: A descriptive analysis was conducted for all AEs reported to the Food and Drug Administration Adverse Event Reporting System for 4 PDE5Is-avanafil, sildenafil, tadalafil, and vardenafil-indicated for erectile dysfunction between January 2010 and December 2021...
October 2023: Sexual Medicine
https://read.qxmd.com/read/38033148/unmasking-hidden-risks-the-surprising-link-between-pde5-inhibitors-and-seizure-susceptibility
#31
JOURNAL ARTICLE
Alex Luiz Menezes da Silva, Chirlene Pinheiro Nascimento, Julianne Elba Cunha Azevedo, Luana Rodrigues Vieira, Akira Otake Hamoy, Allan Carlos da Silva Tiago, João Cleiton Martins Rodrigues, Daniella Bastos de Araujo, Dielly Catrina Favacho Lopes, Vanessa Jóia de Mello, Moisés Hamoy
BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5i) are the first line treatment for erectile dysfunction; however, several articles and case reports have shown central nervous system effects, that can cause seizures in susceptible patients. This study aims to describe the changes caused by the use of Sildenafil and Tadalafil through the analysis of abnormalities expressed in the electrocorticogram (ECoG) of rats and evaluate the seizure threshold response and treatment of seizures with anticonvulsants...
2023: PloS One
https://read.qxmd.com/read/38032134/postmicturition-dribble-in-men-with-no-previous-urogenital-surgery-systematic-review-and-meta-analysis-of-treatment-modalities
#32
REVIEW
Ahmed Albakr, Walid El Ansari, Mohammed Mahdi, Heba Megahed, Merilyn Lock, Mohamed Arafa, Hanaa Al Hothi, Ardalan Ghafouri
INTRODUCTION: Postmicturition dribble (PMD) is common in males. Little is known about PMD etiology, but it is either secondary to urethral/prostatic surgery or primary (no previous surgery). Despite PMD's high prevalence, the effectiveness of its treatment modalities remains lacking. OBJECTIVE: To undertake a systematic review of the available treatments for primary PMD in adult males and meta-analysis of their effectiveness. MATERIALS AND METHODS: We searched four electronic databases from inception to 2023 for original articles that evaluated PMD treatments in male adults without previous urethral/prostatic surgery (PROSPERO protocol CRD42023444591)...
November 30, 2023: Neurourology and Urodynamics
https://read.qxmd.com/read/38019570/identification-of-emotional-spectrums-of-patients-taking-an-erectile-dysfunction-medication-ontology-based-emotion-analysis-of-patient-medication-reviews-on-social-media
#33
JOURNAL ARTICLE
Youran Noh, Maryanne Kim, Song Hee Hong
BACKGROUND: Patient medication reviews on social networking sites provide valuable insights into the experiences and sentiments of individuals taking specific medications. Understanding the emotional spectrum expressed by patients can shed light on their overall satisfaction with medication treatment. This study aims to explore the emotions expressed by patients taking phosphodiesterase type 5 (PDE5) inhibitors and their impact on sentiment. OBJECTIVE: This study aimed to (1) identify the distribution of 6 Parrot emotions in patient medication reviews across different patient characteristics and PDE5 inhibitors, (2) determine the relative impact of each emotion on the overall sentiment derived from the language expressed in each patient medication review while controlling for different patient characteristics and PDE5 inhibitors, and (3) assess the predictive power of the overall sentiment in explaining patient satisfaction with medication treatment...
November 29, 2023: Journal of Medical Internet Research
https://read.qxmd.com/read/37982667/the-relationship-between-the-history-of-pde5-inhibitors-assumption-and-melanoma-a-systematic-review
#34
REVIEW
Simone Cilio, Giulia Briatico, Gabriella Brancaccio, Federico Capone, Matteo Ferro, Ciro Imbimbo, Andrea Salonia, Giuseppe Argenziano, Felice Crocetto
INTRODUCTION: Phosphodiesterase 5 inhibitors (PDE5-is) are used worldwide as first line therapy for erectile dysfunction (ED). Current literature reported data on the warning association between PDE5-is use and the development of cutaneous melanoma. However, these data are contrasting, thus we aim to summarise evidence regarding this association. CONTENT: A systematic review of all published articles related to the effects of PDE5-is in the development of cutaneous melanoma was performed...
November 21, 2023: Journal of Basic and Clinical Physiology and Pharmacology
https://read.qxmd.com/read/37981232/breast-cancer-resistance-protein-limits-fetal-transfer-of-tadalafil-in-mice-bcrp-limits-fetal-transfer-of-tadalafil
#35
JOURNAL ARTICLE
Tomohiro Nishimura, Mari Ishii, Hiroaki Tanaka, Saki Noguchi, Tomoaki Ikeda, Masatoshi Tomi
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is a candidate therapeutic agent for fetal growth restriction and hypertensive disorders of pregnancy. In this study, we elucidated the fetal transfer of tadalafil in comparison with that of sildenafil, the first PDE5 inhibitor to be approved. We also examined the contributions of multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP) to fetal transfer. Tadalafil or sildenafil was administered to wild-type, Mdr1a/b-double-knockout or Bcrp-knockout pregnant mice by continuous infusion from gestational day (GD) 14...
November 17, 2023: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/37973393/erectile-response-profiles-of-men-using-pde5-inhibitors-combined-with-intracavernosal-injections-as-part-of-a-penile-rehabilitation-program-after-radical-prostatectomy
#36
JOURNAL ARTICLE
Thiago P Furtado, Eduardo P Miranda, Serkan Deveci, Lawrence Jenkins, Joseph Narus, Christian Nelson, John P Mulhall
BACKGROUND: Phosphodiesterase type 5 (PDE5) inhibitor labeling states that these agents should not be used in conjunction with other erectogenic medications for fear of priapism occurring. AIM: We explored the risk of priapism and prolonged erections in men in our post-radical prostatectomy (RP) penile injection program who were using regular PDE5 inhibitor and intracavernosal injections (ICIs) as part of their rehabilitation program. METHODS: The study cohort included men on penile injection therapy who (1) were taking tadalafil 5 mg daily or taking sildenafil 25 mg on noninjection days, (2) had an RP, (3) were using their respective PDE5 inhibitor regularly at the time of penile injection training, and (4) complied with the program instructions regarding penile injection use...
November 16, 2023: Journal of Sexual Medicine
https://read.qxmd.com/read/37963482/-pulmonary-hypertension-associated-with-left-heart-disease-group-2
#37
JOURNAL ARTICLE
Kai Helge Schmidt, Olympia Bikou, Rüdiger Blindt, Leonhard Bruch, Ralf Felgendreher, Wolfgang Hohenforst-Schmidt, Stephan Holt, Dennis Ladage, Elena Pfeuffer-Jovic, Andreas Rieth, Alexander Schmeisser, Katharina Schnitzler, Stefan Stadler, Regina Steringer-Mascherbauer, Athiththan Yogeswaran, Wolfgang M Kuebler
Pulmonary hypertension associated with left heart disease (PH-LHD) corresponds to group two of pulmonary hypertension according to clinical classification. Haemodynamically, this group includes isolated post-capillary pulmonary hypertension (IpcPH) and combined post- and pre-capillary pulmonary hypertension (CpcPH). PH-LHD is defined by an mPAP > 20 mmHg and a PAWP > 15 mmHg, pulmonary vascular resistance (PVR) with a cut-off value of 2 Wood Units (WU) is used to differentiate between IpcPH and CpcPH...
November 2023: Pneumologie
https://read.qxmd.com/read/37957534/vardenafil-alleviates-cigarette-smoke-induced-chronic-obstructive-pulmonary-disease-by-activating-autophagy-via-the-ampk-mtor-signalling-pathway-an-in-vitro-and-in-vivo-study
#38
JOURNAL ARTICLE
Weihao Li, Jingxia Yan, Jing Xu, Liqin Zhu, Cuijuan Zhai, Yajuan Wang, Yuxin Wang, Ying Feng, Huifang Cao
Chronic obstructive pulmonary disease (COPD) has always attracted global attention with its high prevalence, incidence rate, and mortality. Exposure to cigarette smoke is one of main causes of COPD. Therefore, it is still necessary to study its pathogenesis and find new therapeutic strategies for early COPD prevention and treatment. Vardenafil, a type 5 phosphodiesterase (PDE5) inhibitor, is known to have an efficient therapy in some cardiovascular, pulmonary, and vascular diseases, which is an important mechanism for COPD...
November 13, 2023: In Vitro Cellular & Developmental Biology. Animal
https://read.qxmd.com/read/37951363/a-cost-analysis-of-phosphodiesterase-type-5-inhibitors-in-the-united-states
#39
JOURNAL ARTICLE
Behnam Nabavizadeh, Amanda Nguyen, Diane Li, Jeroen van Meijgaard, Benjamin N Breyer
OBJECTIVE: To perform a cost analysis of generic and brand-name PDE5 inhibitors at different dosages and pharmacies across the US. METHODS: Using an all-payer retail pharmacy-claims database, we analyzed prescription drug data for three generic and six brand-name oral PDE5 inhibitors at different dosages across US chain and independent pharmacies in 2019. RESULTS: We obtained cash price data from 60,186 pharmacies (35,976 chain and 24,210 independent)...
November 9, 2023: Urology
https://read.qxmd.com/read/37929840/phosphodiesterase-5-inhibitors-pde5i-for-the-treatment-of-raynaud-s-phenomenon
#40
REVIEW
Nancy Maltez, Lara J Maxwell, Fadumo Rirash, Elizabeth Tanjong Ghogomu, Sarah E Harding, Paul C Tingey, George A Wells, Peter Tugwell, Janet Pope
BACKGROUND: Raynaud's phenomenon is a vasodilatory phenomenon characterised by digital pallor, cyanosis, and pain of the extremities. Primary Raynaud's phenomenon has no underlying disease associated with it, while secondary Raynaud's phenomenon is associated with connective tissue disorders such as systemic sclerosis. Systemic sclerosis causes fibrosis and commonly affects the skin and internal organs such as the gastrointestinal tract, lungs, kidney, and heart. Phosphodiesterase 5 inhibitors (PDE5i) are a class of drugs that increases blood flow to the extremities and may be beneficial in the treatment of Raynaud's phenomenon...
November 6, 2023: Cochrane Database of Systematic Reviews
keyword
keyword
22765
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.